Downloads
Abstract
Background: Cutaneous melanoma is the leading cause of death among all skin cancer despite its low prevalence. Pembrolizumab has been approved in Viet Nam for treating advanced and metastatic cutaneous melanoma since 2017. We conduct this research to examine the real - world efficacy and safety profile of pembrolizumab for advanced and metastatic melanoma at Ho Chi Minh City Oncology Hospital.
Methods: Retrospective descriptive study on recurrent, advanced and metastatic cutaneous melanoma patients who were treated by pembrolizumab at Breast, Gastroenterology, Hepatic and Urology Department in Ho Chi Minh City oncology hospital since 1/1/2018 to 30/4/2023.
Results: Median follow - up was 15,63 months, among all patients, 1 (5,6%) achieved complete response, 4 (22,2%) partial response and 8 (44,4%) reached stable disease. Median OS was 15,93 months, Kaplan - Meier 1- year and 2 - year survival rates were 67% and 32,6%, respectively; and median duration of response was 9,83 months. Median PFS was 5,4 months, Kaplan - Meier 6 - month and 12 - month progression free survival rates were 38% and 30,4%, respectively. Univariate analysis shows that patient who archieved disease control had better survival rate than patient who progressed. Most adverse events were grade 1, including skin - related (13,64%), fatigue (13,64%), transaminitis (9,09%), diarrhea (4,54%), neutropenia (13,64%) and anaemia (9,09%).
Conclusions: This study shows that pembrolizumab is more effective than cytotoxic chemotherapy in the firstline treatment of advanced and metastatic cutaneous melanoma. Pembrolizumab is well tolerated and can potentially archieve durable response, which improves the prognosis for patients.
References
Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature.2013; 499(7457): 214-218.
Li H, van der Merwe PA, Sivakumar S. Biomarkers of response to PD-1 pathway blockade. Br J Cancer. 2022; 126(12): 1663-1675.
Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022; 33(9): 929-938.
Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2020; 38(1): 11-19.
Liu FX, Ou W, Diede SJ, Whitman ED. Real-world experience with pembrolizumab in patients with advanced melanoma: A large retrospective observational study. Medicine (Baltimore). 2019; 98(30): e16542.
Mohr P, Scherrer E, Assaf C, Bender M, Berking C, Chandwani S, et al. Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. 2022; 14(7): 1804.
Casarotto E, Chandwani S, Mortier L, Dereure O, Dutriaux C, Dalac S, et al. Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database. Immunotherapy. 2021; 13(11): 905-916.
Robert C, Carlino MS, McNeil C, Ribas A, Grob J-J, Schachter J, et al. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. Journal of Clinical Oncology. 2023: JCO.22.01599.
Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. Jama. 2016; 315(15): 1600-9.
Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet. 2014; 383(9919): 816-27.
Bottlaender L, Amini-Adle M, Maucort-Boulch D, Robinson P, Thomas L, Dalle S. Cutaneous adverse events: a predictor of tumour response under anti-PD-1 therapy for metastatic melanoma, a cohort analysis of 189 patients. J Eur Acad Dermatol Venereol. 2020; 34(9): 2096-2105.
Nguyen LHD, Điều trị toàn thân mêlanôm da giai đoạn tiến xa không phẫu thuật được hoặc di căn. 2021.
| Published | 26-12-2024 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 91 (2023) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.91.8 | |
| Keywords | Mêlanôm da, pembrolizumab, liệu pháp miễn dịch, dữ liệu đời thực Cutaneous melanoma, pembrolizumab, immunotherapy, real - world data |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Journal of Clinical Medicine Hue Central Hospital